# US 2021/0261497 A1 · Spak kinase inhibitors as neuroprotective agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261497 A1
- Document ID: US20210261497A1
- Status: Published application
- Kind: A1
- Application number: 17/177,056
- Filed: 2021-02-16
- Published: 2021-08-26
- Earliest claimed: 2018-10-02
- Assignees: The United States Government as represented by the Department of Veterans Affairs; University of Pittsburgh of the Commonwealth of Higher Education; Xiamen University; University of Exeter
- Applicants: United States Government as represented by the Department of Veterans Affairs; The University of Pittsburgh - of the Commonwealth of Higher Education; Xiamen University; University of Exeter
- Inventors: Dandan Sun; Xianming Deng; Jinwei Zhang; Mohammad Iqbal Hossain Bhuiyan; Bradley J. Molyneaux
- Web page: https://patentgrep.com/patent/US20210261497A1

## CPC

- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07C 255/44: at least one of the singly-bound nitrogen atoms being acylated
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07C 323/62: having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

## Claims

### Claim 1

A method for treating a hypoxic brain injury in a subject, the method comprising the step of administering to the subject an effective amount of at least one compound selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is selected from:

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is selected from:

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is:

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject has been diagnosed with a need for treatment of a hypoxic brain injury prior to the administering step.

### Claim 8 (depends on 1)

The method of claim 1, further comprising the step of identifying a subject in need of treatment of a hypoxic brain injury.

### Claim 9 (depends on 1)

The method of claim 1, wherein the effective amount is a therapeutically effective amount.

### Claim 10 (depends on 1)

The method of claim 1, wherein the effective amount is a prophylactically effective amount.

### Claim 11 (depends on 1)

The method of claim 1, wherein the hypoxic brain injury is associated with dysregulation of SPAK kinase.

### Claim 12 (depends on 1)

The method of claim 1, wherein the hypoxic brain injury is due to traumatic brain injury, ischemic stroke, carbon monoxide poisoning, drowning, choking, suffocating, or cardiac arrest.

### Claim 13 (depends on 1)

The method of claim 1, wherein the hypoxic brain injury is due to ischemic stroke.

### Claim 14

A method for treating a hypoxic brain injury associated with dysregulation of SPAK kinase in a subject, the method comprising the step of administering to the subject an effective amount of a compound having a structure:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject is a mammal.

### Claim 16 (depends on 14)

The method of claim 14, wherein the subject is a human.

### Claim 17 (depends on 14)

The method of claim 14, wherein the effective amount is a therapeutically effective amount.

### Claim 18 (depends on 14)

The method of claim 14, wherein the effective amount is a prophylactically effective amount.

### Claim 19 (depends on 14)

The method of claim 14, wherein the hypoxic brain injury is due to traumatic brain injury, ischemic stroke, carbon monoxide poisoning, drowning, choking, suffocating, or cardiac arrest.

### Claim 20 (depends on 14)

The method of claim 14, wherein the hypoxic brain injury is due to ischemic stroke.
